News

Rheumatologists, researchers, and patients have joined forces on a global scale to better understand how COVID-19 affects people with rheumatic diseases, including those with systemic lupus erythematosus (SLE). The COVID-19 Global Rheumatology Alliance registry, which had more than 100 cases within one week of launching, “represents…

Lupus significantly affects mobility and the ability to conduct everyday activities, according to a global World Lupus Federation survey. Results of the questionnaire, which surveyed more than 4,000 people from more than 70 countries, were released in conjunction with Lupus Awareness Month, observed each May, and with…

Despite the COVID-19 outbreak, ample online ways exist to mark Lupus Awareness Month, observed each May to call attention to lupus and raise funds for research and education. The national effort is coordinated by the Lupus Foundation of America (LFA), which estimates that…

FFF Enterprises and Bionews announced today that both rare and orphan disease advocates are joining forces to provide patients with resources to help them connect as a community and continue to manage their health during this time when many are finding themselves alone. Recognized as the nation’s leading supplier of…

While there are few silver linings to the cloud created by COVID-19, the pandemic that has killed tens of thousands, hobbled economies worldwide and drove millions to quarantine in their homes, one may be a new appreciation of telemedicine. “If something good could come out of this crisis, it’s that…

Lupus Therapeutics, an affiliate of the Lupus Research Alliance (LRA), announced that it is working to design and run a clinical trial into whether hydroxychloroquine and other therapies for systemic lupus erythematosus (SLE) can prevent or ease symptoms of COVID-19 in SLE patients. “This initiative is being done in…

The U.S. Food and Drug Administration (FDA) has granted fast track designation to RemeGen‘s RC18 (telitacicept) to treat people with systemic lupus erythematosus (SLE). A therapy candidate is put on the FDA’s fast track program if it can treat serious conditions and fill an unmet clinical need, either because no…

RemeGen has received $100 million in private financing to continue advancing RC18 (telitacicept), its lead treatment candidate for autoimmune diseases like systemic lupus erythematosus (SLE) now in a pivotal clinical trial. The funding will also support the China-based company’s early stage treatment discovery platform, help expand its manufacturing…

People with systemic lupus erythematosus (SLE) who have been in remission for at least a year and take low-dose prednisone as maintenance therapy have less risk of a disease relapse than those who stop taking it, a recent study suggests. The study, “Withdrawal of low-dose prednisone in…

Adding the experimental oral therapy voclosporin to standard treatment is safe, and its use more than doubles complete kidney responses in people with lupus nephritis, results from the Phase 3 AURORA study show. Aurinia Pharmaceuticals, the company developing voclosporin, plans to finish its rolling application to the U.S. Food…